Search research articles
Contact Us
Filters
Showing results (101-110 of 136) with videos related to
Page
of 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
JTO Clinical and Research Reports
|
March 7, 2023
Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter Study
Jingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.
Clinical Lung Cancer
|
November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
James Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Isamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer
|
February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol
Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.
Clinical Lung Cancer
|
August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2018
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
Jonathan W Riess, David R Gandara, Garrett M Frampton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Alison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Plos One
|
November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
Michael E Goldberg, Meagan Montesion, Lauren Young, et al.
Molecular Cancer Therapeutics
|
February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Nicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 136) with videos related to
Sort By:
Page
of 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
JTO Clinical and Research Reports
|
March 7, 2023
Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter Study
Jingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.
Clinical Lung Cancer
|
November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
James Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Isamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer
|
February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol
Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.
Clinical Lung Cancer
|
August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2018
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
Jonathan W Riess, David R Gandara, Garrett M Frampton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Alison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Plos One
|
November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
Michael E Goldberg, Meagan Montesion, Lauren Young, et al.
Molecular Cancer Therapeutics
|
February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Nicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Page
of 14